Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours

Clin Oncol (R Coll Radiol). 2006 Feb;18(1):88-9. doi: 10.1016/j.clon.2005.08.012.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Capecitabine
  • Cyclooxygenase 2 / metabolism
  • Cyclooxygenase 2 Inhibitors / therapeutic use*
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Drug Therapy, Combination
  • Fluorouracil / analogs & derivatives
  • Humans
  • Lactones / therapeutic use*
  • Middle Aged
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / metabolism
  • Neuroendocrine Tumors / secondary
  • Sulfones / therapeutic use*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antimetabolites, Antineoplastic
  • Cyclooxygenase 2 Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib
  • Deoxycytidine
  • Capecitabine
  • Cyclooxygenase 2
  • Fluorouracil